BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

433 related articles for article (PubMed ID: 14515284)

  • 21. Therapeutic consequences from molecular biology for gastrointestinal stromal tumor patients affected by neurofibromatosis type 1.
    Mussi C; Schildhaus HU; Gronchi A; Wardelmann E; Hohenberger P
    Clin Cancer Res; 2008 Jul; 14(14):4550-5. PubMed ID: 18628470
    [TBL] [Abstract][Full Text] [Related]  

  • 22. A prospective, multicenter, phase 2 study of imatinib mesylate in korean patients with metastatic or unresectable gastrointestinal stromal tumor.
    Ryu MH; Kang WK; Bang YJ; Lee KH; Shin DB; Ryoo BY; Roh JK; Kang JH; Lee H; Kim TW; Chang HM; Park JO; Park YS; Kim TY; Kim MK; Lee WK; Kang HJ; Kang YK
    Oncology; 2009; 76(5):326-32. PubMed ID: 19307738
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Surgical management after neoadjuvant imatinib therapy in gastrointestinal stromal tumours (GISTs) with respect to imatinib resistance caused by secondary KIT mutations.
    Haller F; Detken S; Schulten HJ; Happel N; Gunawan B; Kuhlgatz J; Füzesi L
    Ann Surg Oncol; 2007 Feb; 14(2):526-32. PubMed ID: 17139461
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Efficacy and safety of imatinib mesylate in advanced gastrointestinal stromal tumors.
    Demetri GD; von Mehren M; Blanke CD; Van den Abbeele AD; Eisenberg B; Roberts PJ; Heinrich MC; Tuveson DA; Singer S; Janicek M; Fletcher JA; Silverman SG; Silberman SL; Capdeville R; Kiese B; Peng B; Dimitrijevic S; Druker BJ; Corless C; Fletcher CD; Joensuu H
    N Engl J Med; 2002 Aug; 347(7):472-80. PubMed ID: 12181401
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Role of imatinib mesylate (Gleevec/Glivec) in gastrointestinal stromal tumors.
    de Jong FA; Verweij J
    Expert Rev Anticancer Ther; 2003 Dec; 3(6):757-66. PubMed ID: 14686698
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Characteristics of KIT-negative gastrointestinal stromal tumours and diagnostic utility of protein kinase C theta immunostaining.
    Lee HE; Kim MA; Lee HS; Lee BL; Kim WH
    J Clin Pathol; 2008 Jun; 61(6):722-9. PubMed ID: 18381383
    [TBL] [Abstract][Full Text] [Related]  

  • 27. [Imatinib in gastrointestinal stromal tumor treatment--results from University Hospital Centre Zagreb].
    Vrbanec D; Petricević B; Majerović M; Stern-Padovan R; Belev B; Skegro M; Herceg D; Plestina S; Dedić-Plavetić N; Jakić-Razumović J
    Lijec Vjesn; 2006; 128(5-6):161-6. PubMed ID: 16910417
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Response to imatinib mesylate of a gastrointestinal stromal tumor with very low expression of KIT.
    Bauer S; Corless CL; Heinrich MC; Dirsch O; Antoch G; Kanja J; Seeber S; Schütte J
    Cancer Chemother Pharmacol; 2003 Mar; 51(3):261-5. PubMed ID: 12655446
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Successful resection of a giant recurrent gastrointestinal stromal tumour with imatinib mesylate as neoadjuvant therapy.
    Yu JR; Yang XJ; Yang WL; Gao Y; Zhang Q
    Scand J Gastroenterol; 2007 Sep; 42(9):1138-40. PubMed ID: 17710683
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Pathologic and molecular heterogeneity in imatinib-stable or imatinib-responsive gastrointestinal stromal tumors.
    Agaram NP; Besmer P; Wong GC; Guo T; Socci ND; Maki RG; DeSantis D; Brennan MF; Singer S; DeMatteo RP; Antonescu CR
    Clin Cancer Res; 2007 Jan; 13(1):170-81. PubMed ID: 17200352
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Gastric GI stromal tumors (GISTs): the role of surgery in the era of targeted therapy.
    Heinrich MC; Corless CL
    J Surg Oncol; 2005 Jun; 90(3):195-207; discussion 207. PubMed ID: 15895440
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Clinical significance of oncogenic KIT and PDGFRA mutations in gastrointestinal stromal tumours.
    Lasota J; Miettinen M
    Histopathology; 2008 Sep; 53(3):245-66. PubMed ID: 18312355
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Gastrointestinal stromal tumors (GISTs): a pathology view point.
    Sornmayura P
    J Med Assoc Thai; 2009 Jan; 92(1):124-35. PubMed ID: 19260254
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Successes and challenges in translational research: the development of targeted therapy for gastrointestinal stromal tumours.
    Renouf DJ; Wilson L; Blanke CD
    Clin Cancer Res; 2009 Jun; 15(12):3908-11. PubMed ID: 19509180
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Acquired resistance to imatinib and secondary KIT exon 13 mutation in gastrointestinal stromal tumour.
    Bertucci F; Goncalves A; Monges G; Madroszyk A; Guiramand J; Moutardier V; Noguchi T; Dubreuil P; Sobol H
    Oncol Rep; 2006 Jul; 16(1):97-101. PubMed ID: 16786129
    [TBL] [Abstract][Full Text] [Related]  

  • 36. KIT immunohistochemistry and mutation status in gastrointestinal stromal tumours (GISTs) evaluated for treatment with imatinib.
    Loughrey MB; Trivett M; Beshay V; Dobrovic A; Kovalenko S; Murray W; Lade S; Turner H; McArthur GA; Zalcberg J; Waring PM
    Histopathology; 2006 Jul; 49(1):52-65. PubMed ID: 16842246
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Decrease of CD117 expression as possible prognostic marker for recurrence in the resected specimen after imatinib treatment in patients with initially unresectable gastrointestinal stromal tumors: a clinicopathological analysis.
    Mearadji A; den Bakker MA; van Geel AN; Eggermont AM; Sleijfer S; Verweij J; de Wilt JH; Verhoef C
    Anticancer Drugs; 2008 Jul; 19(6):607-12. PubMed ID: 18525320
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Gastrointestinal stromal tumor.
    Gupta P; Tewari M; Shukla HS
    Surg Oncol; 2008 Aug; 17(2):129-38. PubMed ID: 18234489
    [TBL] [Abstract][Full Text] [Related]  

  • 39. [Gastrointestinal stromal tumors: a broad clinical spectrum from incidental -discovery to acute gastrointestinal bleeding].
    Siewert E; Tietze L; Maintz C; Geier A; Dietrich CG; Matern S; Gartung C
    Z Gastroenterol; 2004 Mar; 42(3):233-42. PubMed ID: 15022111
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Imatinib mesilate for the treatment of gastrointestinal stromal tumour.
    Cassier PA; Dufresne A; Arifi S; El Sayadi H; Labidi I; Ray-Coquard I; Tabone S; Méeus P; Ranchère D; Sunyach MP; Decouvelaere AV; Alberti L; Blay JY
    Expert Opin Pharmacother; 2008 May; 9(7):1211-22. PubMed ID: 18422477
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 22.